Pharmacotherapy for Hepatocellular Carcinoma (HCC): Therapeutic Updates, Best Practices, and Emerging Therapies
Cost: FreeView Offer chevron_right
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths and one of the more common types of cancer affecting the population worldwide.
After completing Pharmacotherapy for Hepatocellular Carcinoma (HCC): Therapeutic Updates, Best Practices, and Emerging Therapies physicians will better be able to:
- Apply existing guideline recommendations in the diagnosis of HCC
Identify present and emerging pharmacotherapeutic treatments for management of unresectable HCC and apply them to patient cases using evidence-based medicine.
- Describe how to manage challenges that arise during treatment with present and emerging pharmacotherapeutic treatments for HCC, including adverse effect management, and apply that knowledge to a patient case
- Describe the challenges associated with treating patients with HCC, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat the disease, and apply that information in optimizing patient care in a patient case
Target Audience: medical oncologists, hepatologists, interventional radiologists, endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with HCC, and. patients and/or their caregivers may also derive benefit from participating in the learning activity.